SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment (Q38619164)

4 September 2017

SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment (English)

1 reference

4 September 2017

1 reference

André J Scheen

1

1 reference

PubMed ID

26513131

4 September 2017

language of work or name

English

0 references

publication date

29 October 2015

1 reference

Expert Opinion on Drug Safety

4 September 2017

1 reference

4 September 2017

14

1 reference

4 September 2017

1879-1904

1 reference

4 September 2017

12

1 reference

SGLT inhibitors in management of diabetes

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

SGLT2 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Renal glucose reabsorption inhibitors to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin: a review of its use in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Weight management in type 2 diabetes: current and emerging approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

SGLT2 inhibitors: their potential reduction in blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Safety of canagliflozin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

SGLT2 Inhibitors May Predispose to Ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effects of dapagliflozin on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Possible adverse effects of SGLT2 inhibitors on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Effects of SGLT2 inhibitors on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

SGLT2 versus DPP4 inhibitors for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1100167

10.1517/14740338.2015.1100167

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26513131